spacer
home > ebr > winter 2019 > embracing a new lease of life
PUBLICATIONS
European Biopharmaceutical Review

Embracing a New Lease of Life

EBR:What are the advantages of drug repurposing in comparison to developing a new drug?

Alex Kiselyov: There are notable advantages of drug repurposing which include the understanding of molecular target, pathway, or network pharmacology, as well as a chance to identify agents that ‘make sense’ from the point of view of signalling mechanisms involved in the disease pathology. It can also provide an insight into molecular biophysics, lead-like properties as exemplified by solubility, lipophilicity, plasma protein binding, and metabolic stability.

There is opportunity for a rapid analoging based on either chemotype, biological profile (fingerprint), or both. If desired, potential to establish new intellectual property (IP) is possible via medicinal chemistry or a structurebased drug discovery route using known or suspected molecular targets for the molecule. For pharmaceutical companies with a large compound collection (library), there is a chance to select target-based or structurebased ‘similars’ with clear IP. Furthermore, another advantage is a frequently detailed understanding of in vivo and clinical (human) safety, dosing regimens, pharmacokinetics (PK), and pharmacodynamics (PD), including specific target engagement in a tissue of relevance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Alex Kiselyov, at Genea Biocells, has over 20 years of industry experience in drug discovery and development. He has contributed to multiple clinical programmes encompassing oncology, cardiovascular disease, dementias and cognitive disorders, and spinal muscular atrophy. His latest endeavour included identification of the targeted treatment for facioscapulohumeral dystrophy that received orphan drug designation in May 2018. Alex has contributed to over 170 papers and seven book chapters and has 50 awarded patents and patent applications.
spacer
Alex Kiselyov
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PHARM Connect 2019

Life science and business are going to meet at PHARM Connect on the 12-13 of March 2019 in Budapest, Hungary to continue the tradition of providing high calibre, customised professional partnering opportunities for pharma and biotech professionals from Central & Eastern European and beyond and deliver the crucial information they need to excel in their work. The influential annual gathering brings together over 400 global and regional decision-makers, top scientists, industry executives and business development leaders for the ninth time to identify new business opportunities, technologies, state-of-the-art formulation development strategies and to foster exchange of ideas on the role of the sector.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

PHARM Connect Congress 2019

12-13 March 2019, Budapest Congress Center, Hungary

PHARM Connect Congress is the premier networking business event dedicated to pharmaceutical and biotechnology innovations and trends from development through commercialisation in Central and Eastern Europe. The organiser - TEG The Events Group - cordially welcome all lead business professionals, academicians, researchers and peers from the field of pharmaceutical manufacturing and biotechnology to participate in the upcoming Congress.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement